Yahong Pharmaceutical APL-1202 and Baekje Bezeran are combined with neoadjuvant treatment of MIBC to be clinically approved in China

On October 13th, Yahong Medicine announced that its oral drug APL-1202 and BeiGene Baizean® (tislelizumab) combined with neoadjuvant treatment of myometrial invasive bladder cancer (MIBC) clinical research application (IND) was approved by the Center for Drug Evaluation (CDE) of the State Drug Administration of China
.

The study is an open-ended, multi-center international phase I/II clinical study.
The main research objectives include: assessing the safety of combination therapy for MIBC patients, the recommended dose and efficacy of phase II clinical research as a neoadjuvant treatment for MIBC
.

APL-1202 is an oral reversible MetAP2 inhibitor with anti-angiogenesis, anti-tumor activity and regulation of tumor immune microenvironment
.

According to the 2020 Chinese Society of Clinical Oncology (CSCO) Urothelial Carcinoma Diagnosis and Treatment Guidelines, for patients who can tolerate radical bladder cancer surgery, radical cystectomy (Radical Cystectomy) is performed after neoadjuvant chemotherapy if they are tolerant of cisplatin.
, RC) is a Class I recommended treatment plan for MIBC treatment.
The commonly used chemotherapy regimen is the GC regimen (gemcitabine + cisplatin)
.